Mount Sinai Liver Cancer Program, RMTI, Icahn School of Medicine at Mount Sinai, NY.
Mount Sinai Liver Cancer Program, RMTI, Icahn School of Medicine at Mount Sinai, NY.
Surgery. 2018 Apr;163(4):698-702. doi: 10.1016/j.surg.2017.09.058. Epub 2017 Dec 23.
Resection remains the treatment of choice achieving 5-year survival rates of 22% to 40%. The aim of this analysis was to examine the outcomes of patients with solitary ≤5 cm intrahepatic cholangiocarcinoma.
A retrospective chart review was performed on 123 patients undergoing resection for primary intrahepatic cholangiocarcinoma from 1995 to 2013. Group 1 included patients with asymptomatic solitary intrahepatic cholangiocarcinoma measuring ≤5 cm.
Group 1 (n = 33, 27%) had a greater rate of underlying liver disease, cirrhosis, minor resection, favorable pathologic features including decreased rate of perineural invasion, vascular invasion, lymph node involvement, and satellite nodules (P < .05). Factors associated with overall poor outcome were patients in Group 2 (P=.025), positive margin (P=.04), presence of satellite nodules (P = .008), and multinodularity (P=.058). Factors associated with recurrence in Group 1 were presence of satellite nodules (P=.004), and tumor size ≥4 cm (P=.031). Factors associated with decreased survival in Group 1 was transfusion requirement (P = 0.018). The 5-year recurrence and survival rates were (39% vs 67%) and (71% vs 53%) in Group 1 versus Group 2, respectively (P=.111).
Resection of solitary intrahepatic cholangiocarcinoma ≤5 cm can achieve 5-year survival rates up to 71%. Results were comparable to those of patients undergoing transplantation for hepatocellular cancer within the Milan criteria.
切除仍然是治疗的首选方法,可实现 5 年生存率 22%至 40%。本分析的目的是检查单发≤5cm 肝内胆管细胞癌患者的结局。
对 1995 年至 2013 年间接受原发性肝内胆管细胞癌切除术的 123 例患者进行回顾性图表审查。第 1 组包括无症状单发肝内胆管细胞癌,直径≤5cm。
第 1 组(n=33,27%)有更高的基础肝病、肝硬化、小范围切除术、有利的病理特征,包括降低的神经周围侵犯、血管侵犯、淋巴结受累和卫星结节发生率(P<.05)。总体预后不良的相关因素为第 2 组患者(P=.025)、阳性切缘(P=.04)、卫星结节存在(P=.008)和多结节性(P=.058)。第 1 组中与复发相关的因素为卫星结节存在(P=.004)和肿瘤大小≥4cm(P=.031)。第 1 组中与生存时间缩短相关的因素为输血需求(P=.018)。第 1 组的 5 年复发率和生存率分别为(39% vs 67%)和(71% vs 53%),第 2 组分别为(P=.111)。
切除单发≤5cm 的肝内胆管细胞癌可达到 5 年生存率 71%。结果与符合米兰标准的肝细胞癌移植患者相当。